Mersana Financial Statements From 2010 to 2026

MRSN Stock

USD 29.08 0.18 0.62%

Mersana Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mersana Therapeutics' valuation are provided below:

Gross Profit

-35.8 M

Profit Margin

(2.11)

Market Capitalization

145.4 M

Enterprise Value Revenue

2.7506

Revenue

33.2 M

We have found one hundred twenty available fundamental ratios for Mersana Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Mersana Therapeutics' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 31st of January 2026, Market Cap is likely to drop to about 191.4 M. In addition to that, Enterprise Value is likely to drop to about 105 M

Mersana Therapeutics Total Revenue

48.9 Million

Check Mersana Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mersana Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 10.2 M, Depreciation And Amortization of 1.1 M or Interest Expense of 4.7 M, as well as many indicators such as Price To Sales Ratio of 3.7, Dividend Yield of 0.0 or Days Sales Outstanding of 389. Mersana financial statements analysis is a perfect complement when working with Mersana Therapeutics Valuation or Volatility modules.

Build AI portfolio with Mersana Stock

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Mersana Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

178.3 M

166.4 M

119.9 M

Slightly volatile

Other Current Liabilities

18.2 M

22.5 M

12.6 M

Slightly volatile

Total Current Liabilities

50.6 M

71.8 M

37.4 M

Slightly volatile

Other Liabilities

141.3 M

134.6 M

44.5 M

Slightly volatile

Property Plant And Equipment Net

8.1 M

7.8 M

5.7 M

Slightly volatile

Current Deferred Revenue

21 M

25.5 M

16.1 M

Slightly volatile

Accounts Payable

7.9 M

5 M

5.6 M

Slightly volatile

Cash

121.5 M

123.9 M

82.8 M

Slightly volatile

Non Current Assets Total

10.9 M

8.9 M

7.5 M

Slightly volatile

Non Currrent Assets Other

1.5 M

1.1 M

Slightly volatile

Other Assets

722.1 K

760.1 K

1.5 M

Pretty Stable

Cash And Short Term Investments

159.9 M

154.8 M

107.4 M

Slightly volatile

Common Stock Total Equity

4.2 K

8.1 K

3.8 K

Slightly volatile

Common Stock Shares Outstanding

5.9 M

5.6 M

2.3 M

Slightly volatile

Liabilities And Stockholders Equity

178.3 M

166.4 M

119.9 M

Slightly volatile

Non Current Liabilities Total

69.6 M

105.5 M

61.2 M

Slightly volatile

Capital Surpluse

690.9 M

658 M

281.1 M

Slightly volatile

Other Current Assets

4.9 M

2.6 M

3.2 M

Slightly volatile

Other Stockholder Equity

1.1 B

1 B

371.9 M

Slightly volatile

Total Liabilities

120.2 M

177.3 M

98.6 M

Slightly volatile

Deferred Long Term Liabilities

393.3 K

414 K

5.5 M

Slightly volatile

Property Plant And Equipment Gross

11.9 M

19.6 M

8.6 M

Slightly volatile

Total Current Assets

167.4 M

157.4 M

112.4 M

Slightly volatile

Common Stock

14.5 K

13.8 K

5.6 K

Slightly volatile

Property Plant Equipment

17.5 M

16.6 M

6.7 M

Slightly volatile

Net Invested Capital

11.9 M

12.5 M

73.5 M

Pretty Stable

Net Working Capital

136.2 M

85.6 M

106.6 M

Slightly volatile

Capital Stock

9 K

13.8 K

6.1 K

Slightly volatile

Short and Long Term Debt Total

29.6 M

32.9 M

17.3 M

Slightly volatile

Long Term Debt Total

29.7 M

28.3 M

12.1 M

Slightly volatile

Capital Lease Obligations

7.1 M

4.6 M

5.3 M

Slightly volatile

Short and Long Term Debt

15.1 M

14.4 M

3.4 M

Slightly volatile

Short Term Debt

19.7 M

18.8 M

5.6 M

Slightly volatile

Mersana Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

10.2 M

9.7 M

2.8 M

Slightly volatile

Depreciation And Amortization

1.1 M

1.9 M

871.3 K

Slightly volatile

Selling General Administrative

30 M

46.9 M

22.1 M

Slightly volatile

Total Revenue

48.9 M

46.6 M

21.1 M

Slightly volatile

Other Operating Expenses

126.3 M

130.9 M

90.5 M

Slightly volatile

Research Development

89 M

84 M

64 M

Slightly volatile

Cost Of Revenue

1.8 M

1.9 M

37 M

Pretty Stable

Total Operating Expenses

118.9 M

130.9 M

86.2 M

Slightly volatile

Reconciled Depreciation

1.3 M

1.9 M

1.1 M

Slightly volatile

Non Operating Income Net Other

55.6 K

58.5 K

918 K

Slightly volatile

Selling And Marketing Expenses

1.2 M

1.4 M

1.5 M

Slightly volatile

Mersana Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Sale Purchase Of Stock

415.5 K

437.4 K

11.3 M

Slightly volatile

Stock Based Compensation

10.5 M

18.9 M

7.5 M

Slightly volatile

Begin Period Cash Flow

111.3 M

201.3 M

81.4 M

Slightly volatile

Other Cashflows From Financing Activities

463.4 K

487.8 K

9.4 M

Slightly volatile

Depreciation

1.1 M

1.9 M

871.3 K

Slightly volatile

Capital Expenditures

144.2 K

151.8 K

813.5 K

Very volatile

Total Cash From Financing Activities

4.5 M

4.7 M

49.4 M

Slightly volatile

End Period Cash Flow

121.8 M

124.5 M

83 M

Slightly volatile

Change To Netincome

25.1 M

23.9 M

8.9 M

Slightly volatile

Change Receivables

385.4 K

527.9 K

360.5 K

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

3.7

3.89

730

Pretty Stable

Days Sales Outstanding

389

371

201

Slightly volatile

Stock Based Compensation To Revenue

0.35

0.37

25.887

Pretty Stable

Capex To Depreciation

0.0886

0.0932

1.3092

Slightly volatile

EV To Sales

2.03

2.14

520

Pretty Stable

Payables Turnover

8.79

9.24

8.8759

Slightly volatile

Sales General And Administrative To Revenue

0.86

0.91

52.7513

Pretty Stable

Research And Ddevelopement To Revenue

1.54

1.62

188

Pretty Stable

Capex To Revenue

0.0028

0.0029

0.9648

Pretty Stable

Cash Per Share

30.01

31.58

51.7098

Pretty Stable

Days Payables Outstanding

38.83

40.87

109

Very volatile

Net Debt To EBITDA

2.0

1.44

1.4821

Very volatile

Current Ratio

2.82

1.97

2.7095

Slightly volatile

Receivables Turnover

0.97

1.02

10.2253

Slightly volatile

Capex Per Share

0.0294

0.031

0.6779

Slightly volatile

Revenue Per Share

14.27

9.5

13.3806

Slightly volatile

Interest Debt Per Share

6.78

5.96

6.1807

Slightly volatile

Debt To Assets

0.1

0.18

0.1002

Slightly volatile

Days Of Payables Outstanding

38.83

40.87

109

Very volatile

Ebt Per Ebit

1.03

1.08

0.973

Very volatile

Long Term Debt To Capitalization

7.18

6.84

1.348

Slightly volatile

Total Debt To Capitalization

1.42

1.35

0.3669

Slightly volatile

Quick Ratio

2.83

1.97

2.7136

Slightly volatile

Net Income Per E B T

0.81

0.91

0.9889

Slightly volatile

Cash Ratio

2.16

1.55

2.1233

Slightly volatile

Days Of Sales Outstanding

389

371

201

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.12

1.15

1.0442

Very volatile

Fixed Asset Turnover

5.46

6.87

6.0173

Slightly volatile

Debt Ratio

0.1

0.18

0.1002

Slightly volatile

Price Sales Ratio

3.7

3.89

730

Pretty Stable

Asset Turnover

0.23

0.32

0.37

Slightly volatile

Mersana Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

191.4 M

201.5 M

406.9 M

Very volatile

Enterprise Value

105 M

110.5 M

336.9 M

Pretty Stable

Mersana Fundamental Market Drivers

Mersana Upcoming Events

	27th of February 2024 Upcoming Quarterly Report	View
	14th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	27th of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Mersana Therapeutics Financial Statements

Mersana Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Mersana Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	25.5 M	21 M
Total Revenue	46.6 M	48.9 M
Cost Of Revenue	1.9 M	1.8 M
Stock Based Compensation To Revenue	0.37	0.35
Sales General And Administrative To Revenue	0.91	0.86
Research And Ddevelopement To Revenue	1.62	1.54
Revenue Per Share	9.50	14.27
Ebit Per Revenue	(2.08)	(2.19)

Pair Trading with Mersana Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Mersana Stock

0.79	ACLX	Arcellx	Pair Corr
0.76	MBIO	Mustang Bio	Pair Corr
0.76	CRBP	Corbus Pharmaceuticals	Pair Corr
0.7	RANI	Rani Therapeutics	Pair Corr
0.69	EVGN	Evogene	Pair Corr

The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.

The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:

How To Invest In Mersana

Details

Is Mersana Stock a good investment?

Details

What is Mersana Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Will Biotechnology sector continue expanding? Could Mersana diversify its offerings? Factors like these will boost the valuation of Mersana Therapeutics. Expected growth trajectory for Mersana significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mersana Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(13.95)

Revenue Per Share

6.669

Quarterly Revenue Growth

(0.13)

Return On Assets

(0.36)

Return On Equity

(5.05)

Investors evaluate Mersana Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mersana Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mersana Therapeutics' market price to deviate significantly from intrinsic value.

Understanding that Mersana Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mersana Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mersana Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Mersana Financial Statements From 2010 to 2026

Mersana Therapeutics Total Revenue

48.9 Million

Mersana Therapeutics Balance Sheet

Mersana Therapeutics Income Statement

Mersana Therapeutics Cash Flow Statement

Financial Ratios

Mersana Therapeutics Valuation Data

Mersana Fundamental Market Drivers

Mersana Upcoming Events

About Mersana Therapeutics Financial Statements

Pair Trading with Mersana Therapeutics

Moving against Mersana Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY